AI assistant
Sending…
Seres Therapeutics, Inc. — Director's Dealing 2021
Feb 8, 2021
33847_dirs_2021-02-08_3f5e1dd9-0663-4fdf-8289-e80f8a2d1608.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Seres Therapeutics, Inc. (MCRB)
CIK: 0001609809
Period of Report: 2021-02-04
Reporting Person: Young Teresa L. (See Remarks)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-04 | Stock Option (Right to Buy) | $26.34 | A | 90000 | Acquired | 2031-02-03 | Common Stock (90000) | Direct |
Footnotes
F1: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
More from Seres Therapeutics, Inc.
Regulatory Filings
2026
Jun 5
Board/Management Information
2026
Jun 1
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
May 5
Board/Management Information
2026
Mar 2
Director's Dealing
2026
Feb 18
Director's Dealing
2026
Feb 18
Director's Dealing
2026
Feb 18
Director's Dealing
2026
Feb 18
Director's Dealing
2025
Nov 18